Ki‑67 index value and progesterone receptor status can predict prognosis and suitable treatment in node‑negative breast cancer patients with estrogen receptor‑positive and HER2‑negative tumors
Medicina | Free Full-Text | Exploring Biomarkers in Breast Cancer: Hallmarks of Diagnosis, Treatment, and Follow-Up in Clinical Practice
Cyclin A2 and Ki-67 proliferation markers could be used to identify tumors with poor prognosis in African American women with breast cancer
Value of Breast Cancer Molecular Subtypes and Ki67 Expression for the Prediction of Efficacy and Prognosis of Neoadjuvant Chemotherapy in a Chinese Population. - Abstract - Europe PMC
Distinguishing luminal breast cancer subtypes by Ki67, progesterone receptor or TP53 status provides prognostic information | Modern Pathology
Ki‑67 index value and progesterone receptor status can predict prognosis and suitable treatment in node‑negative breast cancer patients with estrogen receptor‑positive and HER2‑negative tumors
The expression of ki-67 by subtypes tumor of breast cancer | Download Scientific Diagram
Factors influencing agreement of breast cancer luminal molecular subtype by Ki67 labeling index between core needle biopsy and surgical resection specimens | Virchows Archiv
Ki-67 (30-9) scoring and differentiation of Luminal A- and Luminal B-like breast cancer subtypes | springermedizin.de
Ki-67-Based Breast Cancer Recurrence Data | Food for Breast Cancer
การแบ่งประเภททางโมเลกุลของมะเร็งเต้านม (Molecular classification of breast cancer) | Asian Archives of Pathology
Subtypes of Breast Cancer - Breast Cancer - NCBI Bookshelf
PRISE EN CHARGE DES CANCERS DU SEIN HORMONODÉPENDANTS
Subtypes of Breast Cancer: Luminal B - StoryMD
PinPointcases - INACTIVE --- Adjuvant systemic treatment of luminal A/B early breast cancer
Progesterone Receptor Status and Ki-67 Index May Predict Early Relapse in Luminal B/HER2 Negative Breast Cancer Patients: A Retrospective Study | PLOS ONE
MCM6 versus Ki-67 in diagnosis of luminal molecular subtypes of breast cancers | Diagnostic Pathology | Full Text
a ROC curve of Ki67 in the luminal samples (Prosigna®); b Sankey... | Download Scientific Diagram
Distinguishing luminal breast cancer subtypes by Ki67, progesterone receptor or TP53 status provides prognostic information | Modern Pathology
Conventional and digital Ki67 evaluation and their correlation with molecular prognosis and morphological parameters in luminal breast cancer | Scientific Reports
Luminal A and luminal B (HER2 negative) subtypes of breast cancer consist of a mixture of tumors with different genotype | BMC Research Notes | Full Text
![PDF] Difference between Luminal A and Luminal B Subtypes According to Ki-67, Tumor Size, and Progesterone Receptor Negativity Providing Prognostic Information | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/a33aa443a365c6282bd5449f8899f125cb99c7a9/3-Table3-1.png "PDF] Difference between Luminal A and Luminal B Subtypes According to Ki-67, Tumor Size, and Progesterone Receptor Negativity Providing Prognostic Information | Semantic Scholar")
PDF] Difference between Luminal A and Luminal B Subtypes According to Ki-67, Tumor Size, and Progesterone Receptor Negativity Providing Prognostic Information | Semantic Scholar
Identifying the Best Ki67 Cut-Off for Determining Luminal Breast Cancer Subtypes Using Immunohistochemical Analysis and PAM50 Genomic Classification - European Medical Journal
![PDF] Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/60a5e17db2ebec70ad7ebb9addd7b2a5f3bf9992/6-Figure1-1.png "PDF] Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer | Semantic Scholar")
PDF] Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer | Semantic Scholar
